The International Convention Centre (ICC), Birmingham September 2017

Size: px
Start display at page:

Download "The International Convention Centre (ICC), Birmingham September 2017"

Transcription

1 The International Convention Centre (ICC), Birmingham September 2017 Unstable Angina is a Medical Condition until proven Cardiology A Pro-Con Debate Dr Derek Connolly BSc (Hons) MB ChB (Edin) Phd (Cantab) FRCP Consultant Interventional Cardiologist Soon to be at the Midland Metropolitan Hospital

2

3 Work on the build is continuing at a lightning pace in what will be one of the biggest emergency departments in Europe

4 WE PUT ACUTE MEDICINE FIRST

5

6

7

8

9 CHD mortality rates by deprivation quintile, men, 1994 to 2008, Great Britain POOR RICH

10 Age standardised CVD death rates per 100,000 in Massive disparity Men Woman Total

11 Geographical disparity

12

13 Explaining the fall in coronary heart disease deaths in England & Wales ,230 fewer deaths in Risk Factors worse +13% Obesity (increase) +3.5% Diabetes (increase) +4.8% Physical activity (less) +4.4% Risk Factors better -71% Smoking -41% Cholesterol -9% Population BP fall -9% Deprivation -3% Other factors -8% Treatments -42% AMI treatments -8% Secondary prevention -11% Heart failure -12% Angina:CABG & PTCA -4% Angina: Aspirin etc -5% Hypertension therapies -3% Unal, Critchley & Capewell Circulation (9) 1101

14

15

16

17

18 Super Low LDL Article available at Slides available at

19 Types of CV Outcomes Endpoint Evolocumab (N=13,784) Placebo (N=13,780) 3-yr Kaplan-Meier rate HR (95% CI) CV death, MI, or stroke ( ) MI ( ) Stroke ( )

20

21

22 F Eur Heart J. 2016;37(3): doi: /eurheartj/ehv320

23

24 STE-ACS & STEMI acute chest pain persistent (>20 min) ST-segment elevation is termed ST-elevation ACS and generally reflects an acute total coronary occlusion. Most patients will ultimately develop an ST-elevation myocardial infarction (STEMI). The mainstay of treatment in these patients is immediate reperfusion by primary angioplasty or fibrinolytic therapy.

25 Primary Angioplasty

26

27 Out of Hospital Cardiac Arrest Null score

28 Takotsubo syndrome Ken Kato et al. Heart 2017;103: Copyright BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved.

29 So should every presumed STEMI be treated by an Interventional Cardiologist?

30 Most ACS is NSTEMI

31

32

33 Total number of doctors per capita

34 Top 20 specialties from the GMC Please note that doctors with more than one speciality will be counted within each speciality and therefore will have been counted more than once. Specialty Rank No. of doctors % of Specialist Register Anaesthetics 1 11, % General (internal) medicine 2 11, % Paediatrics 3 6, % General psychiatry 4 5, % Clinical radiology 5 5, % General surgery 6 5, % Obstetrics and gynaecology 7 4, % Trauma and orthopaedic surgery 8 4, % Ophthalmology 9 2, % Cardiology 10 2, % Histopathology 11 2, % Gastroenterology 12 2, % Respiratory medicine 13 2, % Haematology 14 1, % Emergency medicine 15 1, % Endocrinology and diabetes mellitus 16 1, % Child and adolescent psychiatry 17 1, % Old age psychiatry 18 1, % Urology 19 1, % Otolaryngology 20 1, % Total - 77, %

35 Can every hospital have PCI? Key points: Two cardiac dedicated catheter laboratories are the minimal requirement for a PCI service undertaking emergency cases. Minimum centre volume is 400 cases/year. Minimum of three interventional cardiologists per centre. PPCI centres should have at least two catheter laboratories and 24/7 provision of service for STEMI. PPCI centres should perform an absolute minimum of 100 STEMI/PPCI cases/year.

36 PCI centres

37 The Department of Health View

38 MINAP Annual Public Report April 2013 March 2014.

39

40 In the old days we only had Cardiologists and then

41 What types of Cardiologist are there? Adult congenital heart disease Cardiac imaging Electrophysiology and devices Heart failure Interventional cardiology

42 The Department of Health View

43

44 Grace Score

45

46

47 European Society of Cardiology (ESC) Congress 2017 ESC Rapid Rule-In, Rule-Out Algorithm for NSTEMI Safe, Accurate August 29, 2017 "ESC 0/1-hour algorithm using pooled data from two prospective studies: Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) and Biomarkers in Acute Cardiovascular Care (BACC). They retrospectively identified 4350 patients in these trials who presented with symptoms suggesting an acute MI, excluding patients with STEMI, in 14 centers in six European countries. Of these, 743 patients (17%) were diagnosed with NSTEMI, based on central adjudication by two independent cardiologists. The patients had a mean age of 65, and 67% were male. Blood levels of hs-ctnt (Elecys assay, Roche Diagnostics) and hs-ctni (Architect i2000sr assay, Abbott Diagnostics) were determined from samples taken when the patients presented and then 1 hour later. As specified in the algorithm, based on their hs-ctnt and hs-ctni levels at time 0 and 1 hour, the patients were classified as "rule in," "rule out," or "observe" for NSTEMI. Using hs-ctnt values at time 0 and 1 hour, the 0/1-hour algorithm safely ruled out patients who did not have NSTEMI. The negative predictive value was 99.8%, and the sensitivity was 99.3%. Similarly, the algorithm accurately ruled in NSTEMI. The positive predictive value was 74.7%, and the specificity was 94.5%.

48

49

50

51

52 NICE 2017

53

54 Kaplan Meier survival curves indicating rates of survival in the transferred and non-transferred patients in the propensity score matched cohort. Isuru Ranasinghe et al. Heart 2015;101: Copyright BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved.

55

56 Is there evidence that and invasive strategy is better than a conservative strategy in ACS?

57 July 2, 2008 Early Invasive vs Conservative Treatment Strategies in Women and Men With Unstable Angina and Non ST-Segment Elevation Myocardial Infarction A Meta-analysis Michelle O Donoghue, MD; William E. Boden, MD; Eugene Braunwald, MD; et alchristopher P. Cannon, MD; Tim C. Clayton, MSc; Robbert J. de Winter, MD, PhD; Keith A. A. Fox, MB, ChB; Bo Lagerqvist, MD, PhD; Peter A. McCullough, MD, MPH; Sabina A. Murphy, MPH; Rudolf Spacek, MD, PhD; Eva Swahn, MD, PhD; Lars Wallentin, MD, PhD; Fons Windhausen, MD; Marc S. Sabatine, MD, MPH JAMA. 2008;300(1): Data were combined across 8 trials (3075 women and 7075 men). The odds ratio (OR) for the composite of death, MI, or ACS for invasive vs conservative strategy in women was 0.81 (95% confidence interval [CI], ; 21.1% vs 25.0%) and in men was 0.73 (95% CI, ; 21.2% vs 26.3%) Conclusions In NSTE ACS, an invasive strategy has a comparable benefit in men and high-risk [biomarker positive] women for reducing the composite end point of death, MI, or rehospitalization with ACS..

58 ICTUS trial

59 Timing of invasive angiography not crucial Laurent Bonello et al. JCIN 2016;9: American College of Cardiology Foundation

60 August 2017 Cardiovascular Testing and Clinical Outcomes in Emergency Department Patients With Chest Pain Alexander T. Sandhu, et al JAMA Intern Med. 2017;177(8): privately insured patients ages 18 to 64 years who presented to the ED with chest pain without initial diagnosis consistent with acute ischemia. aged 18 to 64 years with an average age of 44.4 years. A total of patients (57.9%) were women.

61 August 2017 Cardiovascular Testing and Clinical Outcomes in Emergency Department Patients With Chest Pain After risk factor adjustment, testing within 30 days was associated with a significant increase in coronary angiography (36.5 per 1000 patients tested; 95% CI, ) and revascularization (22.8 per 1000 patients tested; 95% CI, ) at 1 year no significant change in AMI admissions (7.8 per 1000 patients tested; 95% CI, 1.4 to 17.0). Early testing within 2 days was also associated with a significant increase in coronary revascularization but no difference in AMI admissions.

62 Previous Next

63

64 Proportion of patients with an event (%) Cumulative incidence, % Proportion of patients with an event (%) Cumulative incidence, % CTCA and Clinical Outcome 1.7 Years of Follow-up CHD Death and Non-Fatal MI CHD Death, Non-Fatal MI and Non-fatal Stroke 5 4 5% 4% HR 0.62 [ ], P= % 4% HR 0.64 [ ], P= % 2% 1% Standard Care CTCA strata 3 3% AllocatedTreatment=2 2 AllocatedTreatment=1 1 2% 1% Standard Care CTCA strata AllocatedTreatment=2 AllocatedTreatment=1 0 CTCA Standard Care 0% Time, days CTCA 0 Standard Care 0% Time, days Follow Up (years) Follow Up (years)

65 RAPID CTCA Trial INCLUSION CRITERIA Patient 18 years with symptoms mandating investigation for suspected or confirmed ACS with at least one of: ECG abnormalities e.g. ST segment depression >0.5 mm; History of ischaemic heart disease (where the clinician assessing patient confirms history based on patient history or available records); Troponin elevation above the 99 th centile of the normal reference range or increase in high sensitivity troponin meeting European Society of Cardiology criteria for rule-in or myocardial infarction (NB troponin assays will vary from site to site; local laboratory reference standards will be used).

66 HeartFlow FFR CT Process A standard cardiac CT scan is performed and the data is uploaded to HeartFlow. HeartFlow Analysts use proprietary software to create a personalized, digital 3D model of the coronary arteries. Powerful computer algorithms solve millions of complex equations to assess the impact that blockages have on blood flow. Physicians interrogate the model and interpret the FFR CT results to assess, vessel-by-vessel, if sufficient blood is reaching the heart. 84

67 HeartFlow FFR CT Results Refer to product Instructions For Use for patient populations in which FFR CT has been clinically evaluated, relevant clinical data, and product warnings. 85

68 Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. Heart Aug 27. Tomography of the HEART (SCOT-HEART) trial of 4146 participants with suspected angina randomised to CTCA. Patients were dichotomised into NICE guidelinedefined possible angina or non-anginal presentations. Primary (diagnostic) endpoint was diagnostic certainty of angina at 6 weeks and prognostic endpoint comprised fatal and non-fatal myocardial infarction (MI)..

69 Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. In the possible angina cohort, CTCA did not change rates of invasive angiography (p=0.481) but markedly reduced rates of normal coronary angiography (HR 0.32 (0.19 to 0.52), p<0.001). In the non-anginal cohort, rates of invasive angiography increased (HR 1.82 (1.13 to 2.92), p=0.014) without reducing rates of normal coronary angiography (HR 0.78 (0.30 to 2.05), p=0.622).

70 Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. At 3.2 years of follow-up, fatal or non-fatal MI was reduced in patients with possible angina (3.2% to 1.9%%; HR 0.58 (0.34 to 0.99), p=0.045) but not in those with non-anginal symptoms (HR 0.65 (0.25 to 1.69), p=0.379).

71 Who should be referred to an Interventional Cardiologist? All STEMI All Higher / Intermediate Risk NSTEMI [lower risk NSTEMI?Rapid ACS] Most stable Bio Marker Negative Angina do not need referred as an inpatient Non cardiac sounding chest pain patients don t need CTCA and do not need investigation

72

73 The International Convention Centre (ICC), Birmingham September 2017 Unstable Angina is a medical condition until proven cardiology : Against Adrian Large Interventional Cardiologist Debbie Jackson Cardiac Nurse Practitioner UHNM, Stoke-On-Trent.

74

75 What do you mean by unstable angina?

76

77

78 What do you mean by unstable angina?

79 What do you mean by unstable angina?

80

81 Who should deal with this

82 to produce this?

83

84

85 The test for unstable angina is talking and listening

86 Less useful

87 Less useful

88 The test for unstable angina

89 Like all tests

90 The ideal

91 Like all tests, its accuracy should be measured regularly?

92 Accuracy requires skill

93 Skill has to be acquired

94 Skill has to be acquired

95 Cardiac Assessment Nurse Team 24 hour service. Any patient with suspected cardiac presentation referred. Admitted to cardiology bed or discharged home with out patient investigations and/or follow up.

96 Chest pain assessment As a team we see a lot of suspected cardiac chest pain. Rapid Access chest Pain Clinics Emergency portals

97 Focus on unstable angina. We get a lot of referrals with suspected unstable angina/acs many are later discharged from ED with a non cardiac diagnosis. Almost everyone with chest pain gets a Troponin followed by a cardiology referral. (that s a debate for another day!) STEMI and NSTEMI relatively easy to identify. Unstable angina takes a bit more work to get right.

98 How to I identify unstable angina? I have been assessing chest pain for the past 5 years. We started out with some really good teaching sessions on chest pain assessment. Courses in health assessment and a cardiology specific masters programme. Mostly its comes down to practice and experience. Self audit is really useful what happened to the patient are you over or underdiagnosing?

99 Unstable angina Transient condition -important not to miss the diagnosis you can prevent a death or non fatal MI. Troponin and ECG often normal or near normal. The clues are all in the patient history. Take account of risk factors too.

100 My top tips. Take the time to get a full history of the chest pain.. If a patient has cardiac sounding pain at rest - when did it first start? (if you dig a bit deeper, there's almost always a period of stable anginal symptoms even if only for a few days, before the development of unstable symptoms) They wont tell you if you don t ask they are often focused on the one episode that brought them to hospital. If you think someone has stable angina ask specifically if they ever get it at rest (watching TV/in bed).

101 My top tips Look out for rapidly increasing episodes of angina/ crescendo symptoms/ excessive GTN use. Episodes may last longer than in stable angina GTN will help. It goes when I take my spray, but then it comes back ADMIT these patients! They are at high risk of imminent MI.

102 Unstable angina is not Prolonged episodes of continuous chest pain with normal Troponin - even when multiple coronary risk factors. If cardiac pain is constant for more than 45 mins, the bloods will be abnormal. Ask about their normal angina is it stable, has it worsened recently?... If not.. You need to look for another cause of the symptoms.

103 So, who should do it?

104 So, who should do it?

105

106

107

108

109 as long as they ve acquired the skill.

110 Suggestion for how to decide Clinical directors / leads of relevant specialties get together. Decide on service lead(s). Choose / design your system Stick to it Invest in it Audit its performance Continually improve it as a team

111 One last thought / opinion

112 One last thought / opinion

113 One last thought / opinion

114 One last thought / opinion

115

116 The International Convention Centre (ICC), Birmingham September 2017 Unstable Angina is a medical condition until proven cardiology : Against Adrian Large Interventional Cardiologist Debbie Jackson Cardiac Nurse Practitioner UHNM, Stoke-On-Trent.

117

118 What do you mean by unstable angina?

119

120

121 What do you mean by unstable angina?

122 What do you mean by unstable angina?

123

124 Who should deal with this

125 to produce this?

126

127

128 The test for unstable angina is talking and listening

129 Less useful

130 Less useful

131 The test for unstable angina

132 Like all tests

133 The ideal

134 Like all tests, its accuracy should be measured regularly?

135 Accuracy requires skill

136 Skill has to be acquired

137 Skill has to be acquired

138 Cardiac Assessment Nurse Team 24 hour service. Any patient with suspected cardiac presentation referred. Admitted to cardiology bed or discharged home with out patient investigations and/or follow up.

139 Chest pain assessment As a team we see a lot of suspected cardiac chest pain. Rapid Access chest Pain Clinics Emergency portals

140 Focus on unstable angina. We get a lot of referrals with suspected unstable angina/acs many are later discharged from ED with a non cardiac diagnosis. Almost everyone with chest pain gets a Troponin followed by a cardiology referral. (that s a debate for another day!) STEMI and NSTEMI relatively easy to identify. Unstable angina takes a bit more work to get right.

141 How to I identify unstable angina? I have been assessing chest pain for the past 5 years. We started out with some really good teaching sessions on chest pain assessment. Courses in health assessment and a cardiology specific masters programme. Mostly its comes down to practice and experience. Self audit is really useful what happened to the patient are you over or underdiagnosing?

142 Unstable angina Transient condition -important not to miss the diagnosis you can prevent a death or non fatal MI. Troponin and ECG often normal or near normal. The clues are all in the patient history. Take account of risk factors too.

143 My top tips. Take the time to get a full history of the chest pain.. If a patient has cardiac sounding pain at rest - when did it first start? (if you dig a bit deeper, there's almost always a period of stable anginal symptoms even if only for a few days, before the development of unstable symptoms) They wont tell you if you don t ask they are often focused on the one episode that brought them to hospital. If you think someone has stable angina ask specifically if they ever get it at rest (watching TV/in bed).

144 My top tips Look out for rapidly increasing episodes of angina/ crescendo symptoms/ excessive GTN use. Episodes may last longer than in stable angina GTN will help. It goes when I take my spray, but then it comes back ADMIT these patients! They are at high risk of imminent MI.

145 Unstable angina is not Prolonged episodes of continuous chest pain with normal Troponin - even when multiple coronary risk factors. If cardiac pain is constant for more than 45 mins, the bloods will be abnormal. Ask about their normal angina is it stable, has it worsened recently?... If not.. You need to look for another cause of the symptoms.

146 So, who should do it?

147 So, who should do it?

148

149

150

151

152 as long as they ve acquired the skill.

153 Suggestion for how to decide Clinical directors / leads of relevant specialties get together. Decide on service lead(s). Choose / design your system Stick to it Invest in it Audit its performance Continually improve it as a team

154 One last thought / opinion

155 One last thought / opinion

156 One last thought / opinion

157 One last thought / opinion

158

Timing of angiography for high- risk ACS

Timing of angiography for high- risk ACS Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional

More information

High Sensitivity Troponin Improves Management. But Not Yet

High Sensitivity Troponin Improves Management. But Not Yet High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Troponin when is an assay high sensitive?

Troponin when is an assay high sensitive? Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

BioRemarkable Symposium

BioRemarkable Symposium BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

Dr Chris Ellis. Consultant Cardiologist Auckland

Dr Chris Ellis. Consultant Cardiologist Auckland Dr Chris Ellis Consultant Cardiologist Auckland CVD Risk Prevention in NZ 2013 & Beyond: The Clinicians View Dr Chris Ellis Cardiologist Green Lane CVS Service, Cardiology Department, Auckland City Hospital

More information

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Chest Pain. Dr Robert Huggett Consultant Cardiologist Chest Pain Dr Robert Huggett Consultant Cardiologist Outline Diagnosis of cardiac chest pain 2016 NICE update on stable chest pain Assessment of unstable chest pain/acs and MI definition Scope of the

More information

DIAGNOSTICS ASSESSMENT PROGRAMME

DIAGNOSTICS ASSESSMENT PROGRAMME DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity

More information

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA

Cardiac Rehabilitation after Primary Coronary Intervention CONTRA DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,

More information

NHS QIS National Measurement of Audit Acute Coronary Syndrome

NHS QIS National Measurement of Audit Acute Coronary Syndrome NHS QIS National Measurement of Audit Acute Coronary Syndrome Things have changed based on the experience and feedback from the first cycle of measurement and, for the better we think! The Acute Coronary

More information

Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER

Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia

More information

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126.

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126. Information for the public Published: 1 July 2011 nice.org.uk About this information NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments

More information

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of

More information

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from

More information

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia

More information

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals

More information

Diagnostics consultation document

Diagnostics consultation document National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,

More information

D DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2

D DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2 Journal of Health Science 2 (2014) 523-528 doi: 10.17265/2328-7136/2014.11.001 D DAVID PUBLISHING Management, Triage and Outcomes of 378 Patients Presenting to the Emergency Department with Chest Pain

More information

Measuring Natriuretic Peptides in Acute Coronary Syndromes

Measuring Natriuretic Peptides in Acute Coronary Syndromes Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health

More information

Intervention: How and to which extent is technology helping us?

Intervention: How and to which extent is technology helping us? Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction

More information

Professor Norman Sharpe. Heart Foundation West Coast

Professor Norman Sharpe. Heart Foundation West Coast Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease

More information

Ischaemic Heart Disease

Ischaemic Heart Disease Ischaemic Heart Disease Katherine Rothwell Case 1 65 yr old female PMHx : Eczema, is a smoker 20/day Comes to see you complaining of central chest pain Present past few months. Comes on when gardening

More information

Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005

Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005 Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary AB London 27/1/2005 Revascularisation in ACS ICTUS MERLIN REACT 4mins 4mins 4mins AB Tony s Comments 15mins ICTUS Comparison of an early

More information

New Stable Chest Pain Guidance in the UK NICE to have, difficult to implement

New Stable Chest Pain Guidance in the UK NICE to have, difficult to implement New Stable Chest Pain Guidance in the UK NICE to have, difficult to implement Dr Tim Fairbairn MBChB, MRCP, PhD Consultant Imaging Cardiologist Liverpool Heart and Chest Hospital, United Kingdom 2010 Risk

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Diagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15

Diagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15 Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

Otamixaban for non-st-segment elevation acute coronary syndrome

Otamixaban for non-st-segment elevation acute coronary syndrome Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Associate Professor Gerry Devlin

Associate Professor Gerry Devlin Associate Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton 9:00-9:15 Secondary Prevention of IHD The Challenge of Secondary Prevention Associate

More information

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer

More information

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction? THEY AINT WHAT THEY USED TO BE Case

More information

Treatment strategies and risk stratification in acute coronary syndromes Damman, P.

Treatment strategies and risk stratification in acute coronary syndromes Damman, P. UvA-DARE (Digital Academic Repository) Treatment strategies and risk stratification in acute coronary syndromes Damman, P. Link to publication Citation for published version (APA): Damman, P. (2013). Treatment

More information

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Chairman, Faculty of Cardiology,

More information

Management of cardiovascular disease - coronary interventions -

Management of cardiovascular disease - coronary interventions - Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science

More information

FastTest. You ve read the book now test yourself

FastTest. You ve read the book now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Acute Coronary Syndrome. Sonny Achtchi, DO

Acute Coronary Syndrome. Sonny Achtchi, DO Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification

More information

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden

More information

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1. Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical

More information

Commissioning for value focus pack

Commissioning for value focus pack Commissioning for value focus pack Clinical commissioning group: NHS MILTON KEYNES CCG Focus area: Cardiovascular disease (CVD) pathway Version 2 June 2014 Contents 1. Background and context About the

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Assessment and immediate management of suspected acute coronary syndrome bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They

More information

The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University

The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University Expert Opinions CCS Vancouver, BC October 23, 2011 Overview of ACS Epidemiology: Global

More information

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, G. PAPANIKOLAOU GH, THESSALONIKI The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH

More information

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment

More information

Cindy L. Grines MD FACC FSCAI

Cindy L. Grines MD FACC FSCAI Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in

More information

Recent community campaigns on

Recent community campaigns on Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry Use of hs troponin testing of patients hospitalised with possible ACS was associated

More information

Adults With Diagnosed Diabetes

Adults With Diagnosed Diabetes Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle  holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :

More information

Attending Physician Statement- Heart Attack

Attending Physician Statement- Heart Attack Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Heart attack / Cardiomyopathy

More information

Mario Plebani University-Hospital of Padova, Italy

Mario Plebani University-Hospital of Padova, Italy Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO

More information

Unstable angina and NSTEMI

Unstable angina and NSTEMI Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the

More information

Myocardial Infarction In Dr.Yahya Kiwan

Myocardial Infarction In Dr.Yahya Kiwan Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting

More information

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.

More information

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor

More information

Approach to Multi Vessel disease with STEMI

Approach to Multi Vessel disease with STEMI Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre

More information

British Cardiac Society. Clinical and laboratory cardiac facilities required in the UK

British Cardiac Society. Clinical and laboratory cardiac facilities required in the UK Page 1 of 15 British Cardiac Society Clinical and laboratory cardiac facilities required in the UK David Hackett Professional Standards & Peer Review Committee December 2004 Summary: Clinical cardiac facilities

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 May 2011 1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 Yes b) If confirmed please provide details on the number of

More information

Supplementary webappendix

Supplementary webappendix Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD

NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD Author affiliations: Cardiovascular Medicine Division, Pisa University Medical School, Pisa, Italy Address for correspondence:

More information

Richard Grocott Mason

Richard Grocott Mason Richard Grocott Mason What to do with a 50 year old man with chest pain? Does the pain sound cardiac? Is this a possible acute coronary syndrome? Does patient have a previous cardiac history? Natural history

More information

Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales

Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales Myocardial Ischaemia National Audit Project (MINAP): Improving data capture and use across South Wales Author Owner Document Reference Alison Turner Cardiovascular Audit and Primary Care Nurse South Wales

More information

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients

More information

Patient referral for elective coronary angiography: challenging the current strategy

Patient referral for elective coronary angiography: challenging the current strategy Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology

More information

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Statin pretreatment and presentation patterns in patients with acute coronary syndromes Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos

More information

A logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool

A logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool EUREGIO III A logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool PURPOSE OF A HEALTH SERVICE To utilise resources allocated to the health

More information

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

An update on the management of UA / NSTEMI. Michael H. Crawford, MD An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB

More information

NSTE ACS. Timing of intervention

NSTE ACS. Timing of intervention NSTE ACS Timing of intervention Timing of intervention in NSTE-ACS What do the guidelines tell us? Any need for immediate invasive approach? No mortality benefit with an early invasive approach? Putting

More information

Subsequent management and therapies

Subsequent management and therapies ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients - MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis

More information

Use of Biomarkers for Detection of Acute Myocardial Infarction

Use of Biomarkers for Detection of Acute Myocardial Infarction Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Pharmaco-Invasive Approach for STEMI

Pharmaco-Invasive Approach for STEMI Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),

More information

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?

More information

FFR-CT Not Ready for Primetime

FFR-CT Not Ready for Primetime FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,

More information

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927

More information

JAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals)

JAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals) JAWDA Waiting Time Guidelines for (Specialized and General Hospitals) January 2019 Page 1 of 22 Table of Contents Executive Summary... 3 About this Guidance... 4 Performance Indicators... 5 APPENDIX -

More information

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting

More information

Benefit of Performing PCI Based on FFR

Benefit of Performing PCI Based on FFR Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided

More information

High-Sensitivity Cardiac Troponin in Suspected ACS

High-Sensitivity Cardiac Troponin in Suspected ACS 15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care

More information

Defining rise and fall of cardiac troponin values

Defining rise and fall of cardiac troponin values Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory

More information

Treatment strategies and risk stratification in non ST elevation acute coronary syndromes Windhausen, A.

Treatment strategies and risk stratification in non ST elevation acute coronary syndromes Windhausen, A. UvA-DARE (Digital Academic Repository) Treatment strategies and risk stratification in non ST elevation acute coronary syndromes Windhausen, A. Link to publication Citation for published version (APA):

More information

Acute Coronary Syndrome

Acute Coronary Syndrome Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with

More information

DECLARATION OF CONFLICT OF INTEREST. None

DECLARATION OF CONFLICT OF INTEREST. None DECLARATION OF CONFLICT OF INTEREST None How low should we go to avoid harm in hypertensives with comorbidities? CORONARY ARTERY DISEASE Prof. Dr. Maria DOROBANTU, FESC,FACC CARDIOLOGY EMERGENCY HOSPITAL

More information

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients

More information

Technical Meeting on: Current Role of Nuclear Cardiology in the Management of Cardiac Diseases Vienna, May 2008 Vienna International Centre

Technical Meeting on: Current Role of Nuclear Cardiology in the Management of Cardiac Diseases Vienna, May 2008 Vienna International Centre Technical Meeting on: Current Role of Nuclear Cardiology in the Management of Cardiac Diseases Vienna, 5-95 9 May 2008 Vienna International Centre Evidence-based Nuclear Cardiology: Imaging of CAD The

More information

Carotid Ultrasound Scans for Assessing Cardiovascular Risk

Carotid Ultrasound Scans for Assessing Cardiovascular Risk Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/carotid-ultrasound-scans-for-assessing-cardiovascularrisk/4004/

More information